Sargramostim

DB00020ApprovedInvestigationalProtein Based TherapiesLeukocyte Growth Factor

Sargramostim is a modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast.

Protein structure of Sargramostim
Mechanism
Curator reviewed
Primary indication
For the treatment of cancer and bone marrow transplantCurator reviewed · 12 structured indications
Formula / weight
C639H1006N168O196S8 · 14434.5 Da
First approval
United States, 1991 · European Union, 2025
Also known as
Sargramostatin
Code names
B1-61012 · DRG-0012
Brand names
  • Leukine

Resolves to

Compound
UNII5TAA004E22CAS123774-72-1ChEMBLCHEMBL1201670
Clinical / RWD
RxNorm69634ATCL03AA09PharmGKBPA164748631
Targets
P15509CSF2RAP26951IL3RAP32927CSF2RBP34741SDC2

What you can answer from here — as of September 12, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
9Drug interactionsStructured to mechanism, not free text
Sign in
320Clinical trialsPhase, status and sponsor resolved per trial
Sign in
12Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
11Marketed productsAcross 2 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 17 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sargramostim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In